Bristol-myers Squibb Compnay

Medarex Inc.

Amgen Inc.

E. R. Squibb Sons, Inc.

Pfizer Corporation

Ono Pharmaceutical Co., Ltd.

Novarock Biotherapeutics, Ltd.

Oxford Biotherapeutics Ltd

Genmab A+s

Haichun Huang

Alan J Korman

Mohan Srinivasan

Mark J Selby

Changyu Wang

Karla Ann Henning

Guodong Chen

Richard Y Huang

Nils Lonberg

Brigitte Devaux

Peter Brams

David B Passmore

Josephine M Cardarelli

Kristopher Toy

Arvind Rajpal

Indrani Chakraborty

Haibin Chen

Michelle Minhua Han

Huiming Li

Alison Witte

Heidi N Leblanc

Ming Lei

Frank Martin

Bingliang Chen

Li-Sheng Lu

Chin Pan

Susan Wong

Aaron Paul Yamniuk

Francis Hall Martin

Andrew A Welcher

Ronald P Gladue

Bryan C Barnhart

Lan Yang

Barrett Richard Thiele

Brian C Varnum

Xueming Qian

Yanli Wu

Wei Liao

Yi Wu

Rory Francis Finn

Liang Schweizer

Kenneth D Wild, Jr

Sandra V Hatcher

Jing Min

Timothy J Paradis

Tie J Zhang

Heather Inoue

Hilary T Chute

Chris Vezina

Wenyan Shen

Maria N Jure-Kunkel

Jonathan Alexander Terrett

Gary Elliott

Mark Yamanaka

Shrikant Deshpande

Steven Kiyoshi Yoshinaga

Martin J Corbett

John S Sack

Jun Zhang

Gerald Siu

Yue-Sheng Li

William James Boyle

Chetana Rao-Naik

Dawn M Tanamachi

Han Li

Vangipuram S Rangan

Tetsuya Ishino

Hans S Keirstead

Eugene Medlock

Yi Pei

Susan Chien-Szu Wong

Tim Sproul

David J King

Steven Lee Bender

Xi-Tao Wang

John Kevin Sullivan

Michelle Renee Kuhne

Michael Aidan North

Gerald Fries Casperson

Xin Jiang

Dana Dan Hu-Lowe

Gang Li

Jianying Wang

Paul Parren

Jie Liu

Ole Baadsgaard

Pavel Strop

Robert F Graziano

Vincent Guerlavais

Sarah Lee Pogue

Jørgen Petersen

Jan G J Van De Winkel

Ekaterina G Deyanova

Martin John Glennie

Jessica Teeling

Bilal Sufi

Natalie Bezman

Liang Chen

Sharon Elaine Boyd

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligand (TL1A). The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TL1A mediated diseases, disorders or conditions.

Tumor necrosis factor-like ligand 1A specific antibodies and compositions and uses thereof

The present disclosure provides antibodies and antibody fragments thereof that bind to IL-23p19. The disclosed antibodies and antibody fragments thereof can modulate a biological activity of the IL-23 receptor signaling axis and are therefore useful for the treatment of immune-mediated inflammatory disorders.

Anti-interleukin-23 P19 antibodies and methods of use thereof

This disclosure provides isolated antibodies that bind specifically to CD27 with high affinity. The disclosure provides methods for treating a subject afflicted with a cancer comprising administering to the subject a therapeutically effective amount of an anti-CD27 antibody as monotherapy or in combination with a checkpoint inhibitor, such as an anti-PD-1, anti-PD-L1, or anti-CTLA-4 antibody.

Anti-CD27 antibodies and uses thereof

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce the antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof

The present invention provides antibodies, or antigen-binding fragment thereof, which specifically bind to tumor necrosis factor (TNF)-like ligandA(TLA) The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of TLA mediated diseases, disorders or conditions.

Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.

Anti-CLauDiN 18 antibodies and methods of use thereof

Provided herein are diagnostic antibodies that bind to glucocorticoid-induced tumor necrosis factor receptor (GITR). Such antibodies are useful for methods of detecting the expression of GITR in biological samples, for example, tumor tissue, and identifying a cancer patient likely to respond to anti-GITR immunotherapy or predicting whether a cancer patient will respond to anti-GITR immunotherapy.

Anti-GITR antibodies for cancer diagnostics

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the invention, including methods for treating various cancers.

Antibodies against CD73 and uses thereof

The disclosure provides antibodies that specifically bind human MICA/B and methods of use thereof. In some aspects, the disclosure is directed to methods of treating a cancer in a subject, comprising administering to the subject an anti-MICA/B antibody.

Antibodies against MICA and/or MICB and uses thereof

Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR)

Provided herein are antibodies, or antigen binding portions thereof, that bind to glucocorticoid-inducible TNF receptor (GITR). Also provided are uses of these proteins in therapeutic applications, such as in the treatment of cancer. Further provided are cells that produce antibodies, polynucleotides encoding the heavy and/or light chain variable region of the antibodies, and vectors comprising the polynucleotides encoding the heavy and/or light chain variable region of the antibodies.

Growing community of inventors

Fremont, CA, United States of America

Haichun Huang